Literature DB >> 17958397

Molecular-targeted antitumor agents. 15. Neolamellarins from the marine sponge Dendrilla nigra inhibit hypoxia-inducible factor-1 activation and secreted vascular endothelial growth factor production in breast tumor cells.

Rui Liu1, Yang Liu, Yu-Dong Zhou, Dale G Nagle.   

Abstract

The transcription factor hypoxia-inducible factor-1 (HIF-1) has emerged as a major antitumor molecular target. Inhibition of HIF-1 activation has been shown to suppress the growth, survival, and metastatic spread of hypoxic tumors. The NCI Open Repository of marine invertebrates and algae lipid extracts was evaluated for HIF-1 inhibitory activity in a T47D human breast tumor cell-based reporter assay. Bioassay-guided chromatographic separation of the active extract from the sponge Dendrilla nigra produced four new lamellarin-like phenolic pyrroles, which most closely resemble the structure of the known D. cactos compound lamellarin O. However, unlike lamellarins, the structures of neolamellarin A (1), neolamellarin B (2), 5-hydroxyneolamellarin B (3), and 7-hydroxyneolamellarin A (4) lack the carboxyl moiety at position C-2 of the substituted pyrrole ring and have a significantly different pattern of oxidation. Compound 4 was found to inhibit hypoxia-induced HIF-1 activation (IC50 1.9 microM) in T47D cells. Hypoxic induction of vascular endothelial growth factor (VEGF), a potent angiogenic factor and HIF-1 target gene, was also inhibited by 4 at the secreted protein level.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17958397      PMCID: PMC2914556          DOI: 10.1021/np070206e

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  18 in total

Review 1.  Hypoxia in cancer: significance and impact on clinical outcome.

Authors:  Peter Vaupel; Arnulf Mayer
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

2.  Suppression of tumor growth through disruption of hypoxia-inducible transcription.

Authors:  A L Kung; S Wang; J M Klco; W G Kaelin; D M Livingston
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

3.  Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth.

Authors:  H E Ryan; M Poloni; W McNulty; D Elson; M Gassmann; J M Arbeit; R S Johnson
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

Review 4.  The biology of VEGF and its receptors.

Authors:  Napoleone Ferrara; Hans-Peter Gerber; Jennifer LeCouter
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

Review 5.  Development of novel therapeutic strategies that target HIF-1.

Authors:  Gregg L Semenza
Journal:  Expert Opin Ther Targets       Date:  2006-04       Impact factor: 6.902

6.  The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy.

Authors:  Annika Unruh; Anke Ressel; Hamid G Mohamed; Randall S Johnson; Roger Nadrowitz; Eckart Richter; Dörthe M Katschinski; Roland H Wenger
Journal:  Oncogene       Date:  2003-05-22       Impact factor: 9.867

Review 7.  Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1).

Authors:  Dale G Nagle; Yu-Dong Zhou
Journal:  Curr Drug Targets       Date:  2006-03       Impact factor: 3.465

Review 8.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

Review 9.  Targeting hypoxia cell signaling for cancer therapy.

Authors:  Giovanni Melillo
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

10.  Molecular-targeted antitumor agents: the Saururus cernuus dineolignans manassantin B and 4-O-demethylmanassantin B are potent inhibitors of hypoxia-activated HIF-1.

Authors:  Tyler W Hodges; Chowdhury Faiz Hossain; Yong-Pil Kim; Yu-Dong Zhou; Dale G Nagle
Journal:  J Nat Prod       Date:  2004-05       Impact factor: 4.050

View more
  10 in total

1.  Marine Natural Products as Inhibitors of Hypoxic Signaling in Tumors.

Authors:  Dale G Nagle; Yu-Dong Zhou
Journal:  Phytochem Rev       Date:  2009-06       Impact factor: 5.374

2.  Two-component approach toward a fully substituted N-fused pyrrole ring.

Authors:  Dmitri Chernyak; Cathy Skontos; Vladimir Gevorgyan
Journal:  Org Lett       Date:  2010-07-16       Impact factor: 6.005

3.  Molecular-targeted antitumor agents. 19. Furospongolide from a marine Lendenfeldia sp. sponge inhibits hypoxia-inducible factor-1 activation in breast tumor cells.

Authors:  Yang Liu; Rui Liu; Shui-Chun Mao; J Brian Morgan; Mika B Jekabsons; Yu-Dong Zhou; Dale G Nagle
Journal:  J Nat Prod       Date:  2008-11-06       Impact factor: 4.050

Review 4.  Marine antitumor drugs: status, shortfalls and strategies.

Authors:  Ira Bhatnagar; Se-Kwon Kim
Journal:  Mar Drugs       Date:  2010-10-15       Impact factor: 5.118

Review 5.  Angiosuppressive properties of marine-derived compounds-a mini review.

Authors:  Patrick Y K Yue; H M Leung; Adela J Li; Tracy N C Chan; T S Lum; Y L Chung; Y H Sung; M H Wong; Kelvin S Y Leung; Eddy Y Zeng
Journal:  Environ Sci Pollut Res Int       Date:  2015-10-31       Impact factor: 4.223

Review 6.  Marine Pyrrole Alkaloids.

Authors:  Kevin Seipp; Leander Geske; Till Opatz
Journal:  Mar Drugs       Date:  2021-09-10       Impact factor: 5.118

Review 7.  Anticancer properties of lamellarins.

Authors:  Christian Bailly
Journal:  Mar Drugs       Date:  2015-02-19       Impact factor: 5.118

Review 8.  Synthetic approaches to the lamellarins--a comprehensive review.

Authors:  Dennis Imbri; Johannes Tauber; Till Opatz
Journal:  Mar Drugs       Date:  2014-12-18       Impact factor: 5.118

Review 9.  Marine Natural Products from New Caledonia--A Review.

Authors:  Sofia-Eléna Motuhi; Mohamed Mehiri; Claude Elisabeth Payri; Stéphane La Barre; Stéphane Bach
Journal:  Mar Drugs       Date:  2016-03-16       Impact factor: 5.118

10.  Protective Effects of Marine Alkaloid Neolamellarin A Derivatives against Glutamate Induced PC12 Cell Apoptosis.

Authors:  Kai Zhang; Xian Guan; Xiao Zhang; Lu Liu; Ruijuan Yin; Tao Jiang
Journal:  Mar Drugs       Date:  2022-04-12       Impact factor: 6.085

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.